x
ServiziMenu principaleHome
You are here: Home > What we do > Future Events > Certificate of Competence in Lymphoma - fifth cohort (CCL5)
Share Print

Certificate of Competence in Lymphoma - fifth cohort (CCL5)

04.02.2021  -  19.05.2022

APPLICATION CLOSED

CERTIFICATE OF COMPETENCE

Description

Certificate of Competence in Lymphoma (CCL) programme
Programme Chairs: James Armitage, US; Franco Cavalli, CH; Manuela Hoechstetter, DE; Stephan Stilgenbauer, DE

The European School of Oncology (ESO) in cooperation with Ulm University has developed a post-graduate curriculum of studies designed for oncologists, haematologists and graduates in natural sciences with experience in oncology,

The objective of the programme is to advance the knowledge and science in the management of lymphoma patients with a curriculum that extends over a period of 15 months and includes three seminars and four e-learning modules.

The programme is academically recognised with 14 European Credit Transfer and Accumulation System Points (ECTS) by Ulm University and upon successful completion, participants obtain an academic certificate and a diploma supplement issued by Ulm University.

The current CCL cohort started in February 2021 and will conclude in May 2022. The subsequent cohort will run from 2023 to 2024. Admission to the programme is by competitive application only and is limited to 25 participants.

Programme

Block 1 - Bellinzona, Switzerland (Virtual)

CCL5: Seminar 1 + LyFE

Block 2 - Online

CCL5: Module 1: Basic research, epidemiology and pathology of lymphoma

Block 3 - Online

CCL5: Module 2: Principles of diagnostics, management and clinical trials

Block 4 - Lugano, Switzerland (Virtual)

CCL5: Seminar 2 + ICML

Block 5 - Online

CCL5: Module 3: Lymphoma subtypes Part 1 - Mature B-cell neoplasms

Block 6 - Online

CCL5: Module 4: Lymphoma subtypes Part 2 - PTLD, T-cell and NK-cell neoplasms and Hodgkin lymphoma

Block 7 - Ulm, Germany

CCL5: Seminar 3

Faculty

James O. Armitage, University of Nebraska Medical Center, Dept. of Oncology and Hematology, Omaha, US
Sally Barrington, St Thomas' Hospital, Nuclear Medicine PET Imaging Centre, London, UK
Francesco Bertoni, IOR Institute of Oncology Research, Lymphoma & Genomics Research Program, Bellinzona, CH
Penelope Bradbury, Princess Margaret Cancer Centre, Divistion of Medical Oncology and Hematology, Toronto, ON, CA
George Calin, The University of Texas MD Anderson Cancer Center, Department of Experimental Therapeutics, Division of Cancer Medicine, Houston, TX, US
Elias Campo, Hospital Clinic of the University of Barcelona, Anatomic Pathology Dept., Barcelona, ES
Luciano Cascione, Institute of Oncology Research (IOR), Faculty of Biomedical Sciences, Bellinzona, CH
Carla Casulo, University of Rochester Medical Center, Dept. of Medicine, Hematology/Oncology, Rochester, US
Franco Cavalli, Oncology Institute of Southern Switzerland, Ufficio Prof. Cavalli, Bellinzona, CH
Bruce D. Cheson, The Lymphoma Research Foundation, Research Dept., New York, US
Joseph M. Connors, University of British Columbia Cancer Agency, Lymphoma Tumor Group, Vancouver, CA
Andrew Davies, General Hospital, Cancer Sciences Division, Somers Cancer Research Building, Southampton, UK
Daphne De Jong, Amsterdam University Medical Centre, Hemato-Pathology Department, Amsterdam, NL
Martin Dreyling, Munich University Hospital, Medical Clinic III, Munich, DE
Kieron Dunleavy, National Cancer Institute, Hemato Oncology Dept., Washington, DC, US
Andreas Engert, University Clinic Cologne, Clinic I for Internal Medicine, Cologne, DE
Pedro Farinha, BC Cancer Agency, BCCA Centre for Lymphoid Cancer, Vancouver, CA
Massimo Federico, University of Modena and Reggio Emilia (UNIMORE), Policlinico, Modena, IT
Andrés J. M. Ferreri, San Raffaele Scientific Institute, Unit of Lymphoid Malignancies, Milan, IT
Francesco Forconi, University Hospital Southampton, Lymphoma clinic, Southampton, UK
Gianluca Gaidano, University of Eastern Piedmont, Haematology Dpt., Novara, IT
Roger Geiger, Institute of Oncology Research (IOR), Faculty of Biomedical Sciences, Bellinzona, CH
Bernhard Gerber, Oncology Institute of Southern Switzerland (IOSI), Haematology Dpt., Bellinzona, CH
Christian Gisselbrecht, St.Louis Hospital, Dept. of Haematology, Paris, FR
Mary Gospodarowicz, Princess Margaret Cancer Centre - University of Toronto, Dept. of Radiation Oncology, Toronto, CA
Anton Hagenbeek, Academic Medical Centre, Dept. of Haematology, Amsterdam, NL
Gerhard Held, Saarland University, Hemato Oncology Dept., Kaiserslautern, DE
Manuela Hoechstetter, Klinikum Schwabing, Klinik für Hämatologie, Onkologie, Immunologie, Palliativmed, Munich, DE
Werner Kempf, Kempf und Pfaltz Practice, Histologische Diagnostik, Zurich, CH
Eva Kimby, Karolinska Institute, Dept. of Hematology, Stockholm, SE
Stefan Knop, University Clinic Würzburg, Haematology Department, Würzburg, DE
Ralf Küppers, University of Duisburg-Essen, Medical School, Institute of Cell Biology (Cancer Research), Essen, DE
Georg Lenz, Universitätsklinikum Münster, Translationale Onkologie Dept., Münster, DE
T. Andrew Lister, St. Bartholomew's Hospital, Dept. of Medical Oncology, London, UK
Stefano Luminari, University of Modena and Reggio Emilia, Oncology Centre of Modena, Modena, IT
Liv Meert, EORTC, Data Management Dept., Brussels, BE
Daniel Mertens, University Hospital of Ulm and German Cancer Research Center DKFZ, Mechanisms of Leukemogenesis Lab, Ulm, DE
Peter Möller, Ulm University Medical Center, Institute of Pathology, Ulm, DE
Silvia Montoto, Queen Mary's School, Institute of Cancer, Barts Cancer Institute/ Centre for Haemato-Oncology, London, UK
Ryan Morin, British Columbia Cancer Agency, Department of Molecular Biology and Biochemistry, Vancouver, CA
Jessica Okosun, Cancer Research UK, Centre for Haemato-Oncology, London, UK
Laura Pasqualucci, Herbert Irving Comprehensive Cancer Center, Institute for Cancer Genetics and Department of Pathology and Cell Biology, New York, US
Jakob R. Passweg, University Hospital Basel, Department of Haematology, Basel, CH
Lorenzo Patocchi, Cryms, DEV, Lamone, CH
Stefano Pileri, European Institute of Oncology, Haematopathology Division, Milan, IT
Alexandros Rampotas, Oxford University Hospitals, ., Oxford, UK
Andrea Rinaldi, IOR - Institute of Oncology Research, Lymphoma and Genomics Program, Bellinzona, CH
Danielle Rodin, Princess Margaret Cancer Centre, Radiation Medicine Program, Toronto, CA
Davide Rossi, Oncology Institue of Southern Switzerland (IOSI), Division of Haematology, Bellinzona, CH
Dietrich Rothenbacher, Ulm University, Institute of Epidemiology and Med. Biometry, Ulm, DE
Uta Schmidt-Strassburger, Ulm University, Learning and Teaching, Medical Faculty, Ulm, DE
Laurie H. Sehn, British Columbia Cancer Agency, Centre for Lymphoid Cancer, Vancouver, CA
Diego Serraino, National Cancer Institute, IRCCS, Centro di Riferimento Oncologico, Aviano, IT
Cristiana Sessa, Istituto Oncologico della Svizzera Italiana, Gynaecology Dpt., Bellinzona, CH
Filippo Spriano, Institute of Oncology Research (IOR), Faculty of Biomedical Sciences, Bellinzona, CH
Anastasios Stathis, Oncology Institute of Southern Switzerland, Div. of Medical Oncology, Bellinzona, CH
Stephan Stilgenbauer, University of Ulm, Dept. of Internal Medicine 3, Haematology and Oncology, Ulm, DE
Mariagrazia Uguccioni, IRB, ., Bellinzona, CH
Julie M. Vose, University of Nebraska Medical Center, Division of Hematology/Oncology, Omaha, Nebraska, US
Emanuele Zucca, Oncology Institute of Southern Switzerland (IOSI), Dept. of Medical Oncology, Bellinzona, CH